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Abstract
The lengthy treatment regimen for tuberculosis is necessary to eradicate a small sub-population of M. tuberculosis that
persists in certain host locations under drug pressure. Limited information is available on persisting bacilli and their location
within the lung during disease progression and after drug treatment. Here we provide a comprehensive histopathological
and microscopic evaluation to elucidate the location of bacterial populations in animal models for TB drug
development. To detect bacilli in tissues, a new combination staining method was optimized using auramine O and
rhodamine B for staining acid-fast bacilli, hematoxylin QS for staining tissue and DAPI for staining nuclei. Bacillary location
was studied in three animal models used in-house for TB drug evaluations: C57BL/6 mice, immunocompromised GKO mice
and guinea pigs. In both mouse models, the bacilli were found primarily intracellularly in inflammatory lesions at most
stages of disease, except for late stage GKO mice, which showed significant necrosis and extracellular bacilli after 25 days of
infection. This is also the time when hypoxia was initially visualized in GKO mice by 2-piminidazole. In guinea pigs, the
majority of bacteria in lungs are extracellular organisms in necrotic lesions and only few, if any, were ever visualized in
inflammatory lesions. Following drug treatment in mice a homogenous bacillary reduction across lung granulomas was
observed, whereas in guinea pigs the remaining extracellular bacilli persisted in lesions with residual necrosis. In summary,
differences in pathogenesis between animal models infected with M. tuberculosis result in various granulomatous lesion
types, which affect the location, environment and state of bacilli. The majority of M. tuberculosis bacilli in an advanced
disease state were found to be extracellular in necrotic lesions with an acellular rim of residual necrosis. Drug development
should be designed to target this bacillary population and should evaluate drug regimens in the appropriate animal models.
Citation: Hoff DR, Ryan GJ, Driver ER, Ssemakulu CC, De Groote MA, et al. (2011) Location of Intra- and Extracellular M. tuberculosis Populations in Lungs of Mice
and Guinea Pigs during Disease Progression and after Drug Treatment. PLoS ONE 6(3): e17550. doi:10.1371/journal.pone.0017550
Editor: Ludovic Tailleux, Institut Pasteur, France
Received October 11, 2010; Accepted February 8, 2011; Published March , 2011
Copyright:  2011 Hoff et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Support was provided by the National Institutes of Health (NIH) grant RO-1 AI061505-01A1 and the NIH Contracts NO1 AI-95385 at Colorado State
University, Fort Collins, and N01-AI-95364 at the Southern Research Institute, Birmingham, AL. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: lenaerts@colostate.edu
Introduction
The standard regimen for tuberculosis (TB) requires 6–9
months of daily, multidrug therapy to achieve sterilization without
relapse [1,2]. The lengthy treatment regimen is thought to be
necessary to eradicate a small sub-population of M. tuberculosis
bacilli that persist in the face of drug pressure [3]. The ability of M.
tuberculosis to adapt to a changing environment and persist in
certain locations of the host despite a vigorous adaptive immune
response, likely contributes to the difficulty in curing TB with
antimicrobial drugs [3–6]. Several in vitro studies to date have
shown that the environment surrounding M. tuberculosis can alter
the metabolic state and replication rate of the bacilli thereby
rendering them refractory to drug treatment [7–11]. In contrast to
the controlled conditions of culture environments in vitro, very little
information is available on the far more complicated in vivo
conditions of the bacteria such as in human lung lesions [5]. We
previously described that M. tuberculosis exists as multiple
populations in most in vitro and in vivo conditions, even within a
seemingly single microenvironment [12]. More understanding of
the bacterial location in the lung throughout disease progression
and the bacterial in vivo microenvironment is needed to elucidate
the host-pathogen interaction further.
Human TB infected lungs generally show a heterogeneity of
lung lesion types often with necrosis in the center and surrounded
by a peripheral rim of fibrosis [13]. A better understanding of
tuberculosis lesion pathogenesis is emerging from evaluating
animal models that demonstrate diverse in vivo responses to
experimental infections. Animal infection models are essential to
vaccine and drug development by generating the data that are a
prerequisite for clinical trials. The standard laboratory mouse
models have provided critical information on the efficacy of a
novel compound in TB drug development as well as on safety and
pharmacokinetics [14–17]. The drawback of the standard mouse
infection models for tuberculosis is their lack of advanced lesion
types as the progression of disease rarely reaches the stages of
extensive necrosis and calcification in the lungs [18]. Numerous
studies have demonstrated that the standard laboratory mouse fails
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21to show significant necrosis and thus hypoxia in lung lesions [19–
21]. Therefore, the addition of a secondary animal model showing
a broad range of pathological features might be necessary at later
stages of TB drug development to assess drug activity against
persisting bacteria in necrotic lesions. Guinea pigs infected with M.
tuberculosis show greater similarities to natural infections in humans,
as these animals show hypoxia, necrosis and calcification [21–25].
Recently, more attention has been brought to the importance of
comparative pathology and pathogenesis in different animal
models [21,26], yet little information is available regarding the
actual location of the bacilli in these pulmonary lesions across
animal models. There are at least two reasons that may explain the
lack of this information. Many animal models showing these
advanced lesion types, such as the non-human primates and the
current rabbit model, show only low bacterial numbers per lesion
which makes visualization in tissue sections very difficult
[21,27,28]. In addition, the staining methods used by most are
labor-intensive and time consuming especially when numerous
organ sections from multiple animals require microscopic
evaluation.
To visualize M. tuberculosis either in tissues or in sputum smears,
the detection method most commonly employed is the Ziehl-
Neelsen (ZN) acid-fast stain [29–35]. Fluorescence is much
preferred over brightfield microscopy because it provides greater
sensitivity at a lower scanning magnification, yielding more
consistent results with less user-fatigue [36–38]. Among the
various acid-fast, fluorochrome staining reagents used in TB
detection, the most common are auramine O and the auramine-
rhodamine (AR) combination. A comprehensive review on the
comparison of the AR and ZN staining techniques to detect M.
tuberculosis in sputum smears demonstrated that both techniques
showed similar specificity, but the AR technique was found to be
more sensitive and facilitated easier microscopic evaluations versus
the ZN stain [39]. One drawback of using fluorescent acid-fast
stains is that tissue architecture is obscured due to the counterstain
that darkens all but the bacilli. Only a few reports describe the use
of AR in combination with other tissue stains on tissue samples
[40–42]. In this study, a combination staining method was
developed to not only identify M. tuberculosis bacilli, but to also
navigate through tissue histology. This method enables bacilli to
be accurately located within tissue sections. In an earlier study, we
described that treatment of guinea pigs with the experimental drug
TMC207 almost completely eradicated bacteria throughout the
lesions, and that some remnants of acid fast bacilli remaining after
treatment were observed to be extracellular, in the acellular rim of
primary necrotic lesions by the Ziehl-Neelsen method [23]. In this
study a thorough, in-depth comparison of the bacterial location in
several animal models was performed during the progression of
disease as well as after drug treatment using the newly developed
combination staining method.
To date, the activity of novel compounds in vivo is generally
measured by the reduction in colony forming units (CFU) from
organ homogenates of infected animals with little knowledge
relating to pathology, location of the bacilli at the start and during
drug treatment, and the effect of drug activity in different locations
in the lung. To address these three aspects, we studied the different
standard animal models used in our laboratory for evaluation of
experimental compounds against tuberculosis ; a short term M.
tuberculosis infection model using immunocompromised IFN-c gene
knockout mice [43], the immunocompetent C57BL/6 mouse
model [44] and the guinea pig model [23,45]. All M. tuberculosis
infections were performed by low dose aerosol infection (using an
initial inoculum of 30–100 CFU in the lungs of the animals). The
ultimate goals of this study were: 1) to understand the pathogenesis
across the animal models in terms of lung lesion pathology and to
record the location of the bacilli, 2) to gain information about drug
effects on the pathology in the different animal models, and 3) to
study the location of the persistent bacterial population remaining
after drug treatment in the lung. A better understanding of the
animal models used in TB drug development is critical in
delineating the in vivo activity of an experimental compound
against certain populations of M. tuberculosis bacteria based on their
location. In addition, this will ensure the use of the appropriate
animal model for the evaluation of new drug classes.
Results
Drug efficacy in immunocompetent vs.
immunocompromised mice
The efficacy of several clinically used TB drugs was evaluated in
our standard C57BL/6 versus GKO mouse model infected via a
low dose aerosol of M. tuberculosis (Fig. 1). At the start of treatment,
the bacterial load in the lungs reached ,7.0 log10CFU in C57BL6
mice (at 21 days after aerosol infection) and 6.2 log10CFU in GKO
mice (at 18 days after aerosol). At the completion of the study (at
28 days after aerosol infection), the bacterial load in the untreated
control group remained largely unchanged for C57BL/6 mice
(P.0.05), whereas the bacillary burden in GKO increased by
more than 1 log10CFU (Fig. 1). The activities of the tested drugs
were evaluated over 7 days with sacrifice point after 2, 5 and 7
days of treatment. INH reduced the bacterial load only slightly
over 7 days in the lungs of the C57BL/6 mice (0.25 log10CFU
reduction), whereas in the immunocompromised GKO mice, INH
showed significant activity mainly over the first 5 days of treatment
(0.85 log10CFU reduction) (P,0.05) (Fig. 1). The difference in
drug activity between the two mouse strains was even more
pronounced with MXF treatment at 100 mg/kg, which reduced
the bacterial load in C57BL/6 mice by 0.85 log10CFU and by
more than 3.5 log10CFU in GKO mice after 7 days of treatment
when compared to untreated mice at the start of treatment
(P,0.05).
Intra- and extracellular stages of M. tuberculosis in lung
lesions of GKO mice
Lung sections from GKO mice were studied for the location of
the bacilli after M. tuberculosis infection. The bacilli were visualized
in lung sections via a modified staining method combining the
auramine O and rhodamine B staining (AR) for acid fast bacteria,
hematoxylin QS for staining tissue and DAPI for staining nuclei.
At 18 days post aerosol infection, which is the start of treatment of
our standard laboratory protocol for this model [43], the lung
tissue sections mainly contained inflammatory lesions consisting
primarily of macrophage (mW) and granulocyte (GC) cell
accumulations arranged in an unorganized manner (Fig. 2A), as
also earlier described [46–48]. Auramine-rhodamine positive
(AR+) bacilli were found uniformly distributed across these
inflammatory lesions (estimated at about 85–90%) (Fig. 2B),
whereas a minority was found in and around airways, blood vessels
and randomly dispersed throughout non-inflamed lung parenchy-
ma. AR+ bacilli were predominantly intracellular during this early
stage of infection within various mono- and multinucleated mW
cell types (Fig. 2C, D). At a later stage (20 to 22 days post aerosol
infection), there was a loss of alveolar septal architecture due to
progressive inflammation and individual cell and lesion necrosis. It
is at this stage that the AR+ bacillary population changes from
being exclusively intracellular to becoming increasingly extracel-
lular within the areas of necrosis. By 28 days post aerosol infection,
which is about one week before mice would succumb to disease
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exhibit extensive lesion necrosis (Fig. 2E, F). Necrotic foci
contained high numbers of both intracellular bacteria [within
mW and multinucleated giant cells (55%)] (Fig. 2G) as well as
extracellular AR+ bacilli [residing in alveolar spaces filled with
necrotic cellular debris (40%)] (Fig. 2H). Few AR+ bacilli (5%)
were visible in and around blood vessels and non-granulomatous
lung parenchyma (Fig. 2I).
In the GKO mouse model, drug treatments start 14 to 18 days
post aerosol exposure of M. tuberculosis and lasts for 9 to 14
consecutive days. After 4 days of drug treatment with INH or RIF
in the GKO mice, there was a minimal effect observed on lesion
histology as well as on the distribution of almost exclusively
intracellular bacilli in the lesions. After 7 days of treatment, an
initial reduction in lesion size and of AR+ bacilli number became
evident. After 10 days of drug treatment, there was minimal
inflammation remaining in the lung pathology. At this time, a
reduction in AR+ bacilli was clearly evident and this reduction was
seen uniformly across the entire tissue section. The AR+ bacilli
were mainly located either within the few remaining inflammatory
lesions or were situated peripherally within the adjacent alveolar
spaces (Fig. 2J). A minority of AR+ bacilli was dispersed in non-
inflamed lung parenchyma (5–10%). The remaining bacilli were
primarily intracellular, which is as expected as treatment was
initiated prior to the onset of necrosis (Fig. 2K, L).
Progression of necrosis and development of hypoxia in
late stage GKO
The necrotic granulomas found in the later stages of M.
tuberculosis infected GKO mice showed similar morphology to
necrotic, hypoxic granulomas observed in M. tuberculosis infected
guinea pigs [22,23,26].
Staining with hematoxylin and eosin showed a distinct increase
in cellular necrosis over time. Early pathology (around 22 days
post-infection) shows the aggregation of predominantly granulo-
cytes within alveolar spaces (Fig. 3A, B). These cellular
accumulations then begin to degenerate as observed by the
progression from intact cells to necrotic, cellular debris (Fig. 2E, F).
The accumulation of nuclear material within the alveolar spaces
lead to an increase in basophilic staining during the progression of
disease.
Confocal microscopy was utilized to confirm whether the
bacteria were intra- or extracellular in the eukaryotic cells.
Immunohistochemistry using anti-tubulin antibodies visualized the
cytoskeleton, in combination with DAPI staining which stained the
nuclei. The integrity or degeneration of the viable eukaryotic cells
was thereby shown by the intactness of the nuclei via the DAPI
staining, as well as by the organization of the tubulin structure via
immunohistochemistry. Since every section is 5 microns only, the
bacilli observed in a microscopy section will be in the same plain of
focus as the viable cells, and the proximity of the bacillary location
to the intact nuclei indicates their intracellular nature. At 18 days
post infection, intact nuclei and highly organized tubulin network
can be observed (Fig. 3C), whereas at day 28 the nuclei are ill-
defined and the cytoskeleton structure is lost (Fig. 3D) indicating
loss of cell viability. Confocal microscopy confirmed this
observation by showing the transition from healthy appearing
nuclei at day 18 (Fig. 3E) to accumulated nuclear debris within
alveoli at day 28 in GKO mice (Fig. 3F).
To determine whether lesions in the lungs of GKO mice
infected with M. tuberculosis are hypoxic, mice were injected i.p.
Figure 1. Numbers of viable M. tuberculosis organisms in lungs of infected IFN-c knock-out and C57BL/6 mice after drug treatment.
Mice were infected with M. tuberculosis strain Erdman and treated with drugs starting 18 to 21 days after aerosol infection; with isoniazid (INH),
rifampin (RIF), ethambutol (EMB), gatifloxacin (Gati) or moxifloxacin (Moxi). Sacrifice times were at 2, 5 and 7 days of drug treatment. Data points
represent mean log10 viable bacilli +/2 standard error present in whole lung homogenates.
doi:10.1371/journal.pone.0017550.g001
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PLoS ONE | www.plosone.org 3 March 2011 | Volume 6 | Issue 3 | e17550Figure 2. Intra-and extracellular M. tuberculosis bacilli in lungs throughout infection from M. tuberculosis infected GKO mice and
after 9 days of INH drug treatment. (AR) auramine-rhodamine, hematoxylin QS and DAPI; (H&E) hematoxylin and eosin. (A) An inflammatory
lesion from lungs of an M. tuberculosis infected GKO mouse 18 days after aerosol infection. The inflammatory lesion shows a mix of macrophages and
granulocytes arranged in an unorganized manner (H&E, 1006magnification). (B) Fluorescent image of an inflammatory lesion from lungs of an M.
tuberculosis infected GKO mouse 18 days after aerosol infection. Intracellular red fluorescent AR+ stained bacilli were predominantly found uniformly
distributed throughout inflammatory lesions at this time (AR, 2006magnification). (C) High magnification fluorescent image of the inflammatory
lesion in figure 2B. The lesion shows intracellular AR+ bacilli located within various macrophage cells (AR, 4006magnification). (D) Cropped image
taken from figure 2C (square) showing multiple AR+ stained bacilli within a single macrophage cell (AR, digital magnification). (E) A necrotic
inflammatory lesion from lungs of an M. tuberculosis infected GKO mouse 28 days after aerosol infection. Multiple foci of intense basophilic staining
are seen in alveolar spaces as they accumulate cellular necrotic debris (H&E staining, 406magnification). (F) High magnification of alveolar spaces
filled with cellular necrotic debris located within the inflammatory lesion depicted in figure 2E (square) (H&E staining, 4006magnification). (G) High
magnification of a non-necrotic area within the inflammatory lesion seen in figure 2E (star) taken from a serial tissue section. Fluorescent image
shows a number of intracellular AR+ stained bacilli residing within macrophages (AR, 10006magnification). (H) High magnification of an alveolar
space filled with necrotic debris located within the inflammatory lesion shown in figure 2E (circle) taken from a serial tissue section. Image shows a
high number of extracellular AR+ stained bacilli residing among cellular necrotic debris situated in alveolar spaces (AR, 10006 magnification). (I)
Fluorescent image of an inflammatory lesion from lungs of an M. tuberculosis infected GKO mouse 28 days after aerosol infection showing
intracellular AR+ stained bacilli within multiple macrophages dispersed in non-granulomatous tissue (AR, 2006magnification). (J) AR+ bacilli within a
remaining inflammatory lesion from lungs of an M. tuberculosis infected GKO mouse after 10 days of INH treatment (AR, 1006magnification). (K)
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euthanasia, as we previously described for the guinea pig model
[23]. Mice were injected 15, 17, 20, 22, 25, and 29 days after
aerosol. Hypoxia was not detected by pimonidazole staining in the
lungs of M. tuberculosis infected GKO mice until 25 days post
aerosol infection (data not shown). By 29 days, pimonidazole was
observed to markedly stain around areas of necrosis in pulmonary
lesions of the GKO mice (Fig. 3G, H). Hypoxia was not detected
within areas of necrosis due to the absence of viable cells for the
pimonidazole to form adducts with. These results indicate that the
Figure 3. The progression of cellular necrosis that occurs within pulmonary inflammatory lesions during M. tuberculosis infection in
GKO mice and the development of hypoxia as revealed by pimonidazole. (AR)=auramine-rhodamine, hematoxylin QS and DAPI;
(H&E)=hematoxylin and eosin. (A) An inflammatory lesion from the lungs of M. tuberculosis infected GKO mice 22 days after aerosol infection. The
lesion shows a number of alveolar spaces beginning to accumulate granulocytes prior to the presence of cellular necrosis (H&E staining, 2006
magnification). (B) High magnification of the area demarcated in figure 3A (circle) showing an alveolus completely occluded with inflammatory
infiltrate (H&E staining, 10006magnification). (C) Fluorescent image of an inflammatory lesion from the lungs of M. tuberculosis infected GKO mice 18
days post-aerosol infection showing a highly organized tubulin network with intact nuclei (Immunofluorescence for Tubulin (green) and MTB (red)
and DAPI (blue). 10006magnification). (D) Immunofluorescent image of an inflammatory lesion from the lungs of M. tuberculosis infected GKO mice
28 days post-aerosol TB (red) infection showing loss of tubulin (green) architecture and degenerated nuclei (blue) indicating loss of cell viability
(10006magnification). (E) Confocal microscopy of an inflammatory lesion from the lungs of M. tuberculosis infected GKO mice 18 days post-aerosol
infection. The nuclei (blue) appear healthy with few numbers of AR+ bacilli (red). (AR staining combined with DAPI; 6306 magnification with
additional 2.56digital zoom). (F) Confocal microscopy of an inflammatory lesion from the lungs of M. tuberculosis infected GKO mice 28 days post-
aerosol infection. Degenerated fragments of inflammatory cell nuclei are within alveoli with a high number of extracellular AR+ bacilli (AR staining
combined with DAPI; 6306magnification with additional 2.56digital zoom). (G) Immunohistochemistry detecting hypoxia (brown) in a necrotic lung
lesion from an M. tuberculosis infected GKO mouse 29 days after aerosol infection. The area of central necrosis (N) is surrounded by epithelioid
macrophages near a major airway. (Hematoxylin counterstain, 406 magnification). (H) High magnification of the area demarcated within the
inflammatory lesion shown in figure 3G (square). The center of alveoli, which is likely hypoxic, is filled with cellular debris and fails to stain due to the
lack of viable cells (Hematoxylin counterstain, 4006magnification).
doi:10.1371/journal.pone.0017550.g003
Higher magnification of the inflammatory lesion seen in figure 2J. The lesion shows that the majority of remaining AR+ stained bacilli are intracellular
within macrophages (AR, 2006magnification). (L) High magnification of the inflammatory lesion seen in figure 2K (square). This fluorescent image
shows AR+ bacilli were predominantly found within macrophage cells comprising the few remaining inflammatory lesions (AR, 10006magnification).
doi:10.1371/journal.pone.0017550.g002
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in humans and other animal models are present in the lungs of
GKO mice.
Intracellular M. tuberculosis in C57BL/6 lungs
The location of bacilli was studied in lung sections from
C57BL/6 mice after M. tuberculosis infection via a modified staining
method combining AR for staining acid fast bacteria, hematoxylin
QS for staining tissue and DAPI for staining nuclei. Four weeks
after M. tuberculosis aerosol exposure, which is the start of drug
treatment in our standard laboratory protocol for this mouse
model [44], the inflammatory lung lesions consisted of large
lymphocyte (LC) aggregates surrounding multiple, smaller accu-
mulations of epithelioid mWs (Fig. 4A) as previously reported
[18,49]. AR+ bacilli (,95%) were found intracellular in the
multiple epithelioid mW aggregates located within the lymphocyte
field (Fig. 4B, 4C). A small proportion of AR+ bacilli (,5%) were
observed in foamy mWs located adjacent to areas of inflammation.
At nine weeks post aerosol infection, most of the inflammatory
lesions displayed a well-defined, highly organized lesion structure
that consisted primarily of a central region of epithelioid mFs and
neutrophils surrounded by a distinct, sometimes incomplete,
lymphocyte rim (Fig. 4D) as previously reported [18,49]. These
lesions sometimes exhibited a mild degree of tissue necrosis
Figure 4. Intracellular M. tuberculosis bacilli in lungs from M. tuberculosis infected C57BL/6 mice, throughout infection and after 6
weeks of MXF drug treatment. (AR) auramine-rhodamine, hematoxylin QS and DAPI; (H&E) hematoxylin and eosin. (A) An inflammatory lesion
from the lungs of an M. tuberculosis infected C57BL/6 mouse 4 weeks after aerosol infection. The cellular architecture of lesions shows a field of
lymphocytes (L) surrounding multiple macrophage aggregates (W) (H&E staining, 2006magnification). (B) An inflammatory lesion from lungs of an M.
tuberculosis infected C57BL/6 mouse 4 weeks after aerosol infection. Intracellular AR+ bacilli were predominantly found within macrophage rich
regions surrounded by lymphocytes (AR, 4006magnification). (C) High magnification of the inflammatory lesion shown in figure 4B (circle) showing
intracellular AR+ stained bacilli within macrophages (AR, 10006 magnification). (D) An inflammatory lesion from the lungs of an M. tuberculosis
infected C57BL/6 mouse 9 weeks after aerosol infection. The lesion shows a distinct rim of lymphocytes (L) surrounding a core of epithelioid
macrophages (W). A layer of foamy macrophages (f) can be seen surrounding the lymphocyte rim (H&E staining, 2006 magnification). (E & F)
Fluorescent images of low (E) and high (F) magnifications of the inflammatory lesion depicted in figure 4D taken from a serial tissue section. The
majority of AR+ bacilli at this time are found in epitheloid mWs( W) located within the lymphocyte cuff (L), whereas a lower number of AR+ bacilli are
located in foamy mWs (f) located at the peripheral edges of inflammation (AR, 1006and 2006magnifications). (G) Inflammatory lesion from the lungs
of a C57Bl/6 mouse infected with M. tuberculosis and treated with moxifloxacin for 6 weeks. Cellular architecture of lesions after 6 weeks of drug
treatment is similar to untreated controls and consist of a mW core (W) surrounded by lymphocytes (L) and foamy mWs (f) (AR, 2006magnification).
(H) High magnification of the peripheral edges of the inflammatory lesion shown in figure 4G. A few remaining AR+ bacilli are found within foamy
macrophages located outside of the lymphocyte cuff (AR, 10006magnification).
doi:10.1371/journal.pone.0017550.g004
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devoid of cellular debris. A distinct increase in AR+ bacilli number
was observed at 9 weeks post aerosol infection, AR+ bacilli (80–
85%) were found intracellular within mFs distributed throughout
the central region of inflammatory lesions within the LC cuff
(Fig. 4E, 4F). Fewer AR+ bacilli (15–20%) were found within
foamy mFs that were located outside of the lymphocyte cuff in the
surrounding alveolar air spaces. AR+ bacilli were not found in the
areas of necrosis.
The location of M. tuberculosis in the lungs of C57BL/6 mice was
studied after 6 weeks of INH, RIF or MXF treatment. Over the 6
weeks treatment, the bacterial burden determined by plating on
agar plates decreased in the lungs from 6.0060.07 Logs in the
untreated control groups to 2.0860.16, 3.0660.38 and 1.7560.07
Log10CFU for INH, RIF and MXF, respectively. The occurrence
of drug resistant colonies after treatment is not an issue in this
model due to the low bacterial load at the start of treatment. After
two weeks of treatment, minimal effect was observed on lesion
pathology and distribution of the intracellular AR+ bacilli across
the pulmonary lesions. After six weeks of therapy the pulmonary
inflammation was markedly reduced, although the same cell
morphology, spatial distribution and degree of necrosis was still
observed in remaining lesions. Despite limited effect on lung lesion
pathology, a clear decrease in the number of AR+ bacilli in lungs
was evident at this time and this reduction was uniform across the
lesion. The bacilli (80–85%) were located intracellularly in
epithelioid mFs within the lymphocyte cuff composing the lesion
cores (Fig. 4G), while the minority (15–20%) were found outside of
the lymphocyte cuff in foamy mFs (Fig. 4H). Remarkably, these
AR+ bacilli could still be visualized in these foamy mFs after drug
treatment. Although AR+ bacilli were often found in close
proximity to necrotic regions, none were found within these
necrotic sites.
Extracellular M. tuberculosis in the primary lung lesions in
guinea pigs
The location of bacilli in guinea pig lung sections was studied by
using the combination staining of AR, hematoxylin QS and DAPI
starting one month after low dose aerosol infection (which is the
start of drug treatment in our standard laboratory protocol for the
guinea pig model) [23,45,50]. Lung sections from guinea pigs
studied four weeks after aerosol infection contained multiple
granulomatous lesions with differing morphologies. The classic
necrotic granulomas (also primary granuloma) were differentiated
from inflammatory lesions (also secondary granuloma) based on
the presence of necrosis surrounded by lymphocytic cell
populations [22,23,25,49,51–53] (Fig. 5A, C). The AR+ bacilli
(,70%) were dispersed predominantly throughout the necrotic
areas of the necrotic granulomas (Fig. 5D, E). The bacilli are
present extracellularly either as small clusters of bacteria or as
single cells (Fig. 5F). Confocal microscopy was then used to
confirm the location of AR+ bacilli within the acellular necrotic
core of these granulomas (Fig. 5G, H). Fewer AR+ bacilli (,20%)
were observed intracellularly within mFs found in close proximity
to necrosis within primary lesions, and very few AR+ bacilli
(,10%) were found within mW cells from secondary lesions.
By 10 weeks post aerosol infection, the necrotic core of the
primary granulomas progressed to a state of complete, dystrophic
calcification [22,52] (Fig. 5I). A modest decrease in AR+ bacilli
was observed, but in contrast to earlier time points, the AR+ bacilli
(95%) were now almost exclusively extracellular within the
necrotic core and surrounding, acellular rim of residual lesion
necrosis in the primary granulomas (Fig. 5J, K). Most secondary
lesions contained very few intracellular, if any, detectable AR+
bacilli (data not shown).
Over the 6 weeks treatment, the bacterial burden determined by
plating on agar plates decreased in the lungs from 5.1260.28
Log10 CFU in the untreated control group to 3.7660.0.1 and
1.7860.26 Log10CFU for INH and TMC207, respectively. The
occurrence of drug resistant colonies is not an issue in this model
due to the low bacterial load at the start of treatment. INH
treatment had a differential effect on the lung pathology of the
primary versus the secondary lesions. Secondary lesions dimin-
ished in size and were largely healed after 6 weeks of INH
treatment as previously reported [23]. Primary granulomas, on the
other hand, required prolonged therapy in order to see visible
resolution of the pathology. Healed secondary lesions within the
pulmonary parenchyma reatain normal alveolar structure except
for thickened alveolar walls and a mild to moderate increase in
cellularity. Healed primary lesions are characteried by residual foci
of dystrophic calcification and fibrosis that replace alvoli or are
ebedded in the fibrous stroma that supports airways and
pulmonary lymphatic and blood vascuature [53]. The AR+
bacterial population in the primary lesions steadily declined
throughout INH treatment. However, the decrease in AR+ bacilli
was far less pronounced in guinea pigs compared to the mouse
infection models treated with the same drugs. Similar to the
untreated controls, the remaining AR+ bacilli (,95%) were
extracellular located in primary granulomas and concentrated
within the necrotic core and acellular rim, with only few
intracellular bacilli in the surrounding mF and lymphocyte region
(Fig. 5L). Very few bacteria (,5%) were found within mW cell
types composing secondary lesions.
Besides INH treatment, we evaluated the highly potent
TMC207 in the guinea pig model to see if more intensive
treatment would ultimately result in visible resolution of the more
advanced necrotic lesions. Drug efficacy data of TMC207 and
INH in the guinea pig model have been reported before [23], and
the drug treatments were repeated for this study also using
intermittent timepoints of 2, 4 and 6 weeks of treatment. Similar to
INH treatment, 6 weeks of TMC207 treatment lead to an almost
complete clearance of secondary lesions in guinea pigs. However,
compared to INH, TMC207 was more effective at resolving some
of the primary granulomas in guinea pigs when administered for 6
weeks. While the numbers of AR+ bacilli were far lower after
TMC207 treatment than after INH treatment, the remaining
AR+ bacilli were predominantly present in the necrotic cores and
surrounding acellular rims of the remaining primary granulomas
(Fig. 5M, N).
Discussion
TB drug discovery and development use a sequence of in vitro
assays and animal models of M. tuberculosis infection to identify and
select active experimental compounds. Mouse models provide
important information regarding pharmacokinetics and in vivo
efficacy of novel compounds [15–17,54–57]. Recently, other
animal models which reflect the progression of lung pathology as
seen in humans (to include necrosis, calcification and fibrosis of
lesions) are being considered in later stages of drug development:
such as the guinea pig [21,26,53,58–61], the rabbit [21,28], the
non-human primate infection model for tuberculosis [27], the
Kramnik mouse [62,63], and more recently the minipig model
[64]. Surprisingly, there is limited to no information on the
location of M. tuberculosis in the most widely used animal models for
TB drug development. Up to date, the in vivo efficacy of a new
compound is primarily measured by the reduction in bacillary load
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PLoS ONE | www.plosone.org 7 March 2011 | Volume 6 | Issue 3 | e17550Figure 5. Location of M. tuberculosis bacilli in lungs from M. tuberculosis infected guinea pigs, throughout infection and after 6 weeks
of INH or TMC207 drug treatment. (AR) auramine-rhodamine, hematoxylin QS and DAPI; (H&E) hematoxylin and eosin. (A, B) Low (A) and high (B)
magnifications of an early primary granuloma in the lungs of M. tuberculosis infected guinea pigs 4 weeks post-aerosol infection. Primary granulomas
are distinguished from secondary lesions by the presence of necrosis (N) (H&E staining, 1006and 10006magnifications). (C) A secondary lesion in
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with little knowledge relating to pathology, location of the bacilli in
the various animal models, or the potential differential drug
activity in various locations in the lung. In this manuscript, we
provide a comprehensive microscopic and histopathologic analysis
of the disease progression of the animal models used in-house for
TB drug development with a main focus on the location of the
bacilli in the lung.
M. tuberculosis is generally thought of as being an ‘intracellular
organism’ living in (and perhaps needing) its host cell, the
macrophage. We show that this is not necessarily the case. M.
tuberculosis bacilli were visualized via a new rapid staining method
combining fluorescent acid-fast AR for staining bacteria, hema-
toxylin QS for staining tissue and DAPI for staining nuclei. This
fluorescent staining method enabled us to easily visualize the
bacteria in the tissue across a whole lung granuloma, whereas in
past studies using the Ziehl-Neelsen method by brightfield
microscopy, only limited information per microscopic field could
be collected using high magnification. Confocal microscopy then
gave us a three dimensional view of M. tuberculosis within a
granuloma. Our earlier work using standard Ziehl-Neelsen
staining suggested that the remaining bacilli after drug treatment
in the guinea pig model were primarily present just inside the zone
of incomplete necrosis within the acellular, fibrotic rim of necrotic
lung lesions [23]. However, with this improved staining and
detection method, the rim proved to be merely one of the
locations. In this comprehensive study, we demonstrate that the
majority of bacteria in the guinea pig model are more central
within the core area of the necrotic lesion. In the mouse models
studied here, we found that the majority of bacilli were indeed
intracellular within macrophages through most of the infection. In
the immunocompetent C57BL6 mice, AR+ bacilli were clearly
intracellular, and this was especially evident in the foamy
macrophages located outside of the lymphocyte region as
described earlier [65,66,67]. In the immunocompromised GKO
model, considerably more bacilli per macrophage were visualized
by the AR staining method. Interestingly, in the late stages of
infection in M. tuberculosis infected GKO mice, the granulomatous
lesions begin to exhibit significant necrosis with the bacilli
progressively becoming extracellular (with about half of the bacilli
eventually being extracellular). The GKO mice form massive
granulomas that contain multiple focal-points of necrotic cellular
debris accumulating in alveolar air spaces. These necrotic areas
increase in number and size and in a late stage can collectively
coalesce into a single core (which is also observed in guinea pig, as
well as in human lesions). As a confirmation of necrosis in the late
stage GKO mouse model, immunofluorescence for tubulin was
used that showed a clear loss of the cytoskeleton structure of the
eucaryotic cells. The presence of macrophages and debris in the
airways in this late stage of the GKO model shows pathological
similarity to lung inflammation in cavitary TB patients. Since an
earlier study using the guinea pig model showed these necrotic
lesions to be hypoxic using pimonidazole [23], this led us to
investigate the oxygen tension in lungs of M. tuberculosis infected
GKO mice. Hypoxia has been postulated as one of the
environmental conditions which transitions mycobacteria in vitro
into a non-replicating phase, thereby affecting their responsiveness
to drugs [7,68]. In the late stage of the GKO model, a clear
hypoxic zone was found at the periphery of the necrotic regions.
The inability of pimonidazole to stain the necrotic tissue itself was
due to the lack of viable cells which are required to enzymatically
create detectable adducts, however this necrotic tissue is also likely
to be hypoxic.
The guinea pig model was studied, which shows more complex
pathology with a heterogeneity of lesion types and stages within
one animal at any one time. The location of bacilli in guinea pig
lung lesions was also studied by fluorescent AR staining.
Intracellular bacilli were present in inflammatory lesions only in
the first weeks after aerosol infection showing equal numbers of
intra- and extracellular bacilli visualized throughout the granulo-
ma. From one month after low dose aerosol infection, the bacilli
were mainly extracellular within the necrotic core and surround-
ing acellular rim of the primary granulomas. The ‘core of the
lesion’ is here referred to as the centre of necrotic guinea pig lesion
that calcifies and mineralizes, whereas the ‘rim of the lesion’ is
defined here as the edge of incomplete necrosis which has not yet
calcifieded. Confocal microscopy clearly showed that the core of
the granuloma is indeed acellular and devoid of intact nuclei and is
the location where most bacteria are. The few intracellular bacilli
found were either located in the outer lymphocyte and epithelioid
macrophage cell layer of primary granulomas or in secondary
lesions, although this latter location rarely contained any
detectable AR+ M. tuberculosis bacilli at all. The reason for finding
only very few acid-fast bacilli in the secondary granulomas is not
entirely clear. The secondary lesions in the guinea pig model are
thought to originate mainly from bacilli after hematogenous
dissemination from the primary lesions, which occurs only after
the immune response is already activated. Therefore, bacillary
replication in the secondary lesions is likely curtailed due to the
now activated immune response [51]. The difference in cytokine
profiles in primary and secondary lesions has been described
earlier by others with secondary lesions showing a strong anti-
inflammatory response [69]. For TB drug development, it is
important to realize that in case of progressive disease most
the lungs of an M. tuberculosis infected guinea pig 4 weeks post-aerosol infection. Secondary lesions are distinguished from primary granulomas by
the lack of central necrosis in the former (H&E staining, 1006magnification). (D, E) Low (D) and high (E) magnifications of a primary granuloma from
the lungs of an M. tuberculosis infected guinea pig 4 weeks after aerosol infection. The majority of AR+ bacilli are extracellular within the necrotic core
(c) (AR, 1006and 2006magnifications). (F) High magnification of area demarcated in figure 5E (square). Extracellular AR+ bacilli in the necrotic core
of primary granulomas exist as single cells or are situated in clusters (AR, 10006magnification). (G, H) Confocal micrographs of a necrotic granuloma
showing an acellular necrotic core (c) with extracellular AR+ bacilli (red) (AR and DAPI, 2006and 6306magnifications). (I) A primary granuloma from
the lungs of an M. tuberculosis infected guinea pig 10 weeks after aerosol infection showing advanced calcification and calcification of the necrotic
core (c) and the acellular rim (R) surrounding the core (H&E staining, 1006magnification). (J) Fluorescent image of a primary lung granuloma from an
M. tuberculosis infected guinea pig 10 weeks after aerosol infection. Extracellular AR+ bacilli are present within the necrotic core (c) and the acellular
rim (R) surrounding the necrotic regions (AR, 2006magnification). (K) Cropped image from figure 5I (square) showing extracellular AR+ stained bacilli
in the acellular rim. (L) Fluorescent image of a necrotic primary lung granuloma from an M. tuberculosis infected guinea pig treated for 6 weeks with
INH. Extra-cellular AR+ bacilli are primarily within the core (c) of the partially calcified lytic necrosis, and to a lesser extent within the acellular,
uncalcified rim (R) (AR, 2006and 4006magnifications). (M) A low magnification of the remnant of a primary lung granuloma in an M. tuberculosis
infected guinea pig treated for 6 weeks with TMC207. The primary granuloma shows a caseous necrotic core (c) surrounded by inflammatory cells
(H&E staining, 1006magnification). (N) Fluorescent image of the caseous necrotic core (c) in the primary lung granuloma shown in figure 5M taken
from a serial tissue section. The few extra-cellular AR+ bacilli remaining after TMC207 treatment are primarily located within the central core of
caseous necrosis (AR, 4006magnification).
doi:10.1371/journal.pone.0017550.g005
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cellular debris and calcified cellular components. TB drug
treatment aims to sterilize lesions from bacteria and should
therefore target to eradicate these initial necrotic lesions from the
extracellular bacteria.
Interestingly, a diffuse pink staining effect was frequently seen
after AR staining in primary necrotic granulomas of the guinea
pigs after day 30 (figure 5L). This pink haze was evident
throughout the necrotic granuloma and was also seen in the
GKO mouse in areas of advanced necrosis at day 28 post infection
(figure 2H) but not earlier, and was never observed in the standard
C57BL/6 mouse. It is not entirely clear what this diffuse staining
represents, however, it is possible that AR staining detects free
mycolic acids either from degraded dead bacilli or from bacilli that
shed mycolic acids, a feature reported for in vitro pellicle-grown M.
tuberculosis [70]. We have shown free mycolic acids to stain readily
with rhodamine but not auramine in our laboratory (data not
shown) in an ongoing study to elucidate the potential target of the
AR stain.
Once the vast differences in bacillary locations in the different
animal models were recorded, we studied the effect of drug
treatment on the clearance of bacilli in these different locations in
the lungs using the new fluorescent acid-fast AR stain combined
with hematoxylin QS and DAPI. Results showed that for both
mouse models the reduction of the AR+ bacilli after drug
treatment was largely homogenous across the lesion. Necrosis
was never seen in the lungs of the drug-treated GKO mice as the
onset of necrosis only occurs late in infection after treatment has
initiated. In the unorganized lesion structure of the GKO mice, a
very rapid clearance of AR+ bacilli was observed, presumably by
the large number of phagocytic cells and macrophages present.
Therefore, the AR staining method can in fact be used for the
GKO model as a readout for drug efficacy. In immunocompetent
mice, clearance of the AR+ bacilli occurs slower . After drug
treatment, the clearance of bacilli is homogenous across the
lesions; the remaining bacilli are intracellular, either in epithelioid
mFs within the LC cuff or in foamy mFs located outside the LC
cuff. Although difficult to quantify, a slight trend was observed of
relatively more bacilli remaining in the foamy mFs versus the
epithelioid mFs after drug treatment. Whether this is due to slower
clearance of dead bacilli by the various macrophage celltypes, or to
the bacilli in the foamy mFs being less responsive to drugs has to
be further investigated. Interestingly, the foamy mFs have more
recently been described as being the key participants in both
sustaining persistent bacteria and contributing to tissue pathology
that leads to cavitation and the release of infectious bacilli [65–
67,71,72]. Cardona et al. hypothesize this foamy macrophage
population to be dynamic and drain from the alveolar spaces
resulting in dissemination and generating intragranulomatous
necrosis [72].
In the guinea pig model of M. tuberculosis infection, drug
treatment reduced the bacterial load in the lungs heterogeneously
over the different lung lesion types. While drug treatment
completely reversed lung inflammation associated with secondary
lesions relatively quickly, the resolution of the primary granulomas
required more intensive treatment regimens [45,53]. These results
are in keeping with classical studies by Smith et al., who showed
that INH, RIF and PZA chemotherapy sterilized secondary lesions
but had far less effect on the primary lesions [73]. None of the
earlier studies, however, described the location of the bacilli in the
lung. We observed that six weeks of INH treatment of M.
tuberculosis guinea pigs only had a moderate effect on the AR+
bacilli visualized mainly present in the primary granulomas,
whereas in the guinea pigs treated with TMC207 for 6 weeks an
almost complete eradication of AR+ bacteria in both lesion types
was observed. The clearance of the bacteria in the necrotic lesions
is generally very slow, and therefore AR staining may not be a
good alternative to CFU enumeration for evaluating drug efficacy
in guinea pigs, unless the bacteria are lysed after drug treatment
(which is in fact observed after TMC207 treatment in vitro,
personal communication, K. Andries). The few remaining AR+
bacilli after TMC207 treatment were found extracellular, in the
core of the primary lesion, a microenvironment of residual
primary lesion necrosis. These observations further highlight the
importance of a TB drug to eradicate the persisting, extracellular
bacteria remaining within the necrotic lesions.
Although acid-fast stains have been used for diagnostic purposes
for decades, the exact cellular component of M. tuberculosis
recognized by the dyes is still being debated. Fuchsin, the main
component of Ziehl-Neelsen and Kinyoun acid-fast stain, has been
shown to stain the vastly complex lipid portion of the
mycobacterial cell wall. However, less is known about the target
of the combined auramine O-rhodamine B stain. Auramine O is
believed to bind to mycolic acids and nucleic acids [74–76].
Although rhodamine B has been used in numerous M. tuberculosis
studies, the exact staining target of M. tuberculosis has yet to be
elucidated [74]. Preliminary studies in our laboratory show that
rhodamine B alone stains M. tuberculosis quite readily in culture and
tissue sections and also stains purified cell wall components (data
not shown). To understand what bacterial population is visualized
with the AR staining method in this study, we need to keep two
characteristics of the stain in mind. First, the AR stain might not
visualize all bacterial populations present in the lesion, we might
not see the earlier described acid-fast negative bacterial subpop-
ulation(s) [77,78]. Recently, we also reported on an acid-fast-
negative but immunofluorescence-positive M. tuberculosis popula-
tion in vitro as well as in vivo [12]. Secondly, the stain cannot
differentiate between live and recently killed, intact [and not yet
cleared] tubercle bacilli. Despite these limitations, the purpose of
the combined staining method was to illustrate the differences in
locations of the AR+ bacilli and their clearance (or lysis) caused by
drug treatment, throughout entire lung sections across our animal
models.
To understand the interaction between immunology, pathology
and the location and state of the M. tuberculosis bacillus, the role of
the immune response was studied by comparing single drug
treatment effects in the immunocompromised GKO mice versus
the immunocompetent C57BL/6 mice. The immune response is
generally believed to be favorable to the host by containing and
aiding in the eradication of bacilli due to the induction of
protective cytokines and other immune molecules [6,79]. From the
perspective of TB therapeutics however, the immune response
appears to be an unfavorable response in that it renders the bacilli
less responsive to drugs, as is shown by the results described here.
Drug activity was found to be far more pronounced for all
compounds evaluated in the GKO mice when compared to the
immunocompetent C57BL/6 mice. Drugs administered were
INH, which is mainly active against replicating bacilli [68], as well
as RIF and/or quinolones (MXF, GATI), which are known to be
effective against replicating bacteria as well as sterilizing
compounds [80,81]. This result is not entirely surprising because
the bacilli are actively replicating in the GKO mice without the
interference of adaptive immunity of the host. In fact, M.
tuberculosis bacteria in GKO mice replicate about once a day,
which is the same replication rate as in vitro cultures. However,
drugs showed far less activity in the C57BL/6 mice with any given
compound when compared to the GKO mice. Earlier papers have
elegantly shown that bacteria are slowing their replication rate in
Visualization of M. tuberculosis in Animal Models
PLoS ONE | www.plosone.org 10 March 2011 | Volume 6 | Issue 3 | e17550immunocompetent mice due to the immune response and show a
changed metabolism in the chronic disease state in mice
[11,36,82]. The results show an advantage of the GKO model
as a first in vivo screen to assess potential in vivo activity. The high
numbers of actively replicating bacilli in GKO mice make for a
large dynamic window when testing novel experimental com-
pounds for in vivo activity.
The findings presented in this paper have at least three
important implications for TB drug development. First, it is
important in TB drug development to realize that the majority of
the bacilli in an advanced disease state are extracellular organisms
located in necrotic lesions, as is also seen in human cavitary disease
[83]. Most mouse models are modeling activity of single
compounds or drug regimens against intracellular bacteria, and
because of this limitation other animal models with a more
progressive pathology are required to evaluate drug efficacy
against potentially persistent, extracellular bacilli in hypoxic,
necrotic lesions. A second implication is that a decrease in
inflammation might not be a good measure of antibactericidal
activity. Recently, different imaging methods have been intro-
duced as methods to follow the effect of TB drug therapy in real
time such as PETscan (which requires the uptake of radio-labeled
glucose by actively metabolizing cells) and CATscan based
imaging modalities [21,63]. Our results show that rapid resolution
of non-necrotic inflammatory lesions (such as the secondary lesion
in the guinea pig model) might not adequately reflect the
bactericidal activity of a drug as these lesions only contain very
few bacilli. And thirdly, the immune response as well as the rapid
structural organization of the tuberculous granuloma is usually
seen as a favorable host response as it contains bacilli locally, thus
preventing the progression of the disease. However, the immune
response and its effect on lung pathology may decrease the drug
responsiveness of the bacilli. In the context of drug therapy, the
necrotic granuloma may in addition also present a physical barrier
to effective treatment and to the host immune response. Therapies
aiming at preventing and minimizing necrosis may be beneficial in
eliminating bacilli that persist in necrotic lesions in the face of
standard TB therapy.
In summary, the differences in host immune response among
the different animal models infected with M. tuberculosis result in a
wide variety of granulomatous lesion types which will eventually
determine efficacy of a TB drug regimen. Increasing our
understanding on lesion morphologies as well as the location of
bacilli among the different animal models is vital to designing
different levels of stringency for testing new drugs.
Materials and Methods
Ethics Statement
All experimental protocols were approved with written consent
by the Animal Care Use Committee of Colorado State University
(approval numbers ACUC # 04-302A-06 and ACUC # 06-
221A-03) which abides by the USDA Animal Welfare Act and the
Public Health Service Policy on Humane Care and Use of
Laboratory Animals.
Bacterial Isolates
The virulent M. tuberculosis Erdman strain (TMC 107; ATCC
35801) has been used as a standard for drug evaluations in mice in
our laboratory, and the strain was propagated as previously
described [14,44]. Briefly, M. tuberculosis Erdman was grown to
mid-log phase in Proskauer-Beck Medium containing 0.05%
Tween 80 (Sigma Chemical Co., St. Louis, MO) and stored in
vials frozen at 270uC until use.
The strain M. tuberculosis H37Rv (Trudeau Institute, Saranac
Lake, NY) has been used as a standard in our laboratory for
guinea pig infection studies [23,84]. M. tuberculosis H37Rv was
grown from low passage seed lots in Proskauer-Beck liquid
medium containing 0.05% Tween 80 to early mid-log phase and
frozen in aliquots at 270uC until needed.
Chemicals and drugs
Isoniazid (INH), rifampin (RIF) and ethambutol (EMB) were
obtained from Sigma Chemical Co. (St. Louis, MO). Moxifloxacin
(MXF) and gatifloxacin (GAT) were kindly provided by Southern
Research Institute (SRI) (Birmingham, AL). All drugs, except for
RIF, were dissolved in water. RIF was dissolved in 100% dimethyl
sulfoxide (DMSO) prior to dilution in distilled water (5% final
DMSO concentration). Drug formulations prepared in distilled
water were prepared weekly and stored at 4uC. For the guinea pig
studies, INH was dissolved in 40% (wt/vol) sucrose and
administered in 1 ml per guinea pig. INH was prepared weekly
in distilled sucrose water and stored at 4uC. TMC207 was kindly
provided by Dr. K. Andries (Tibotec, Belgium) and was prepared
in a hydroxypropyl-ß-cyclodextrin solution (CD) as described
before [23].
Immunocompromised mouse TB infection model
Several experiments using different lengths of treatment were
performed,. Briefly, eight- to ten-week-old female specific
pathogen- free, C57BL/6-Ifngtm1ts (GKO) mice were purchased
(Jackson Laboratories, Bar Harbor, Maine). These mice have a
disrupted interferon-c gene, which renders them highly susceptible
to tuberculosis [47]. The standard infection and treatment
protocol for this model was performed as extensively validated
and previously described [43]. Mice were exposed to a low-dose
aerosol infection with the M. tuberculosis strain Erdman ( TMC 107;
ATCC 35801) in a Glas-Col inhalation exposure system (Glas-Col
Inc., Terre Haute, IN) [14]. One day after low dose aerosol
infection, three mice were euthanized to verify bacterial uptake of
50 to 100 CFU per mouse. Each treatment group consisted of 4–5
mice for every subsequent time point. Treatment was initiated 18
days after low dose aerosol infection (standard protocol) and lasted
up to 28 days after aerosol infection. Untreated mice cannot
succumb to disease 28–30 days after aerosol infection. INH was
administered at 25 mg/kg, GAT and MXF at 100 mg/kg, and all
drugs were administered via oral gavage for 7 days/week. One
control group of untreated, infected mice was euthanized by CO2
inhalation at the start of treatment, and a second control group
after the cessation of treatment. Mice were euthanized after 2, 5, 7,
and 10, days after the start of treatment.
Immunocompetent mouse TB infection model
Several experiments using different lengths of treatment were
performed and the protocols are described below. Six- to 8-week-
old female specific pathogen-free immunocompetent C57BL/6
mice (Charles River, Wilmington, MA) were infected via a low
dose aerosol exposure to M. tuberculosis Erdman. The standard
infection and treatment protocol for this model were performed as
previously described [14,44,85]. Three mice were euthanized one
day post low dose aerosol to verify bacterial uptake of 50 to 100
CFU per mouse.
For the short term treatment experiment, drug treatment
started three weeks after low dose aerosol infection (standard
protocol) and lasted for 7 days. INH was administered at 25 mg/
kg, EMB at 150 mg/kg, MXF at 100 mg/kg and RIF at 10 mg/
kg, and drugs were administered via oral gavage for 7 days.
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treatment.
For the long term treatment experiment, drug treatment was
started 3 weeks post-infection and continued for 12 weeks. Five
infected mice were euthanized at the start of treatment as
pretreatment controls. INH was administered at 25 mg/kg and
RIF at 20 mg/kg, 5 days per week via oral gavage. Mice were
euthanized at 2, 6, and 12 weeks after the start of treatment.
Guinea pig TB infection model
Four to five month-old, female Hartley guinea pigs (Charles
River, Wilmington, MA) weighing approximately 500 g each were
exposed to a low-dose aerosol of M. tuberculosis in a Madison
aerosol chamber device. Our standard infection and treatment
protocol for guinea pigs was followed as previously described
[50,86]. Guinea pigs were delivered a low inoculum resulting in
approximately 20–30 lesions in the lungs. At 30 days post-
infection, 5 guinea pigs were euthanized to determine the bacterial
load at the start of treatment. Each guinea pig was drug treated by
administering each dose in the back of the mouth (5 guinea pigs
per group). Control groups received daily oral administration of
1 ml of 40% (wt/vol) sucrose. Drug treated groups were
administered INH at 30 mg/kg for 5 days per week, or
TMC207 at 15 mg/kg. Earlier pharmacokinetic data using
validated HPLC assays yielded an AUC 0–24 of 18.22 hr*mg/
ml for INH at 30 mg/kg [45]. Our earlier in vivo efficacy data on
TMC207 in the guinea pig model showed the 15 mg/kg dose as a
safe and highly efficacious dose [23].
Bacterial enumeration on agar plates
Mice were euthanized by CO2 inhalation, and left lung lobes
were aseptically removed and disrupted in a tissue homogenizer as
previously described [44]. The number of viable organisms was
determined by plating serial dilutions on nutrient Middlebrook
7H11 agar plates (GIBCO BRL, Gaithersburg, MD) containing
cycloheximide at 10 mg/mL and carbenicillin at 50 mg/mL.
Guinea pigs were euthanized by sodium barbital injection
(Sleepaway; Fort Dodge Laboratories), and organs were aseptically
removed and plated as previously described [23]. Statistical
analysis to assess the significance of treatment efficacy results on
bacterial numbers remaining after drug treatment was performed
for mouse models [44] and guinea pig models [23], as described
before.
Combined staining procedure to visualize bacteria with
AR and surrounding tissue
The caudal right lung lobe for mice and guinea pigs was infused
in situ with 10% neutral-buffered formalin. Four micron thick
paraffin sections were stained with TB Auramine-Rhodamine T as
recommended by Becton-Dickinson (Sparks, MD), with modifica-
tions in order to visualize bacteria in the surrounding lung tissue. A
combination staining method was developed by using both
auramine O and rhodamine B to detect acid fast bacteria (AR;
Becton Dickinson), hematoxylin QS for staining tissue (HQS;
Vector Laboratories, Inc., Burlingame, CA) and 496-diamidino-2-
phenylindole dihydrochloride for staining nuclei (DAPI; Sigma
Chemical Co., St. Louis, MO). Tissue sections were dewaxed in
xylene and rehydrated through a graded alcohol series, then
stained with TB Auramine-Rhodamine T for 30 min. After
washing excess stain with ddH2O, slides were decolorized with TB
Decolorizer TM (BD) until the stain appeared dissolved.
Counterstaining was performed with hematoxylin QS for about
5 sec. After washing excess hematoxylin with ddH2O, slides were
stained for 15 min. with DAPI (200 ng/ml final concentration)
and washed in ddH2O.
Entire lung tissue sections were scored based on: 1) estimating
the number of auramine-rhodamine positive (AR+) bacilli per
tissue section in mice and accurately counting the AR+ bacilli in
guinea pig tissues (numbers are presented as percentages), 2)
bacillary appearance (individual or clustered), and 3) intra or
extra-lesional presence. For mouse lung tissues, bacterial numbers
were generated from 2 non-sequential lung lobe sections for every
timepoint for five mice per treatment group. Scoring sheets were
generated for every lung section with the number of lesions
showing bacilli for every section and the approximate number of
the bacilli per lesion for the C57BL/6 mice (tables not shown). For
the GKO mouse model, the percentages of bacteria present per
lesion versus the whole lesion was estimated due to the high
bacillary burden. For guinea pig tissues, the actual bacterial
numbers were counted from 2 non-sequential lung lobe sections
from three guinea pigs from every treatment group (tables not
shown), for the primary (necrotic) and secondary (inflammatory)
lesions. The improvement of the pathology after drug treatment in
the guinea pig lung was evaluated blindly by a veterinary
pathologist by scoring the lung involvement of the inflammation,
as described earlier [24,45].
Immunofluorescence
Five micron sections of lung tissue were dewaxed in xylene and
rehydrated through graded alcohols. Antigen retrieval was
performed using the Retriever
TM 2100 which pressure cooks at
121uC for 15 minutes using Target Retrieval Buffer solution
S3307 (DAKO, Carpinteria, California). Blocking was performed
with 1% goat serum in PBS (Biomeda, Foster City, California) for
30 minutes. The slides were incubated at 4uC overnight with a
monoclonal mouse anti-tubulin antibody (Cell Signaling Technol-
ogy, Danvers, Massachusetts) and a rabbit polyclonal anti-TB
whole cell lysate minus LAM (Antibody E293, CSU TB Vaccine
Testing and Research Materials Contract, Colorado). Subsequent-
ly, the slides were washed using PBS and the antibody was
detected with an Alexafluor 488 labeled goat anti-mouse IgG and
also an Alexafluor 568 labeled goat anti-rabbit IgG (Invitrogen,
Carlsbad, California). The slides were washed in PBS, mounted
with ProLongH Gold antifade reagent with DAPI (Invitrogen,
Carlsbad, California) and photographed under a fluorescent
microscope.
Hypoxia staining with pimonidazole
Pimonidazole staining was used as described before [19,23] to
detect hypoxic regions in the lungs of GKO mice. Pimonidazole is
a 2-nitroimidazole that is able to identify regions of hypoxia
(,4 mMO 2 saturation or O2 tensions of 10 mm Hg) in animal
organs after injection. Pimonidazole forms protein adducts with
thiol groups in cells adjacent to hypoxic regions and the adducts
are detected with a monoclonal antibody. M. tuberculosis-infected
GKO mice were injected intraperitoneally (i.p.) with pimonidazole
hydrochloride (Chemicon, Hampshire, United Kingdom) at a dose
of 60 mg/kg mouse body weight dissolved in 16 PBS at 1.5 h
prior to sacrifice at days 15, 17, 20, 22, 25, and 29 after low dose
aerosol infection. Five micron thick sections of paraformaldehyde-
fixed, paraffin-embedded tissue were cut and mounted on slides
for processing. Tissue sections were deparaffinized with xylene
before performing antigen retrieval with pronase (Fisher Scientific,
Schwerte, Germany) for 40 min. at 40uC. Endogenous peroxidase
activity was reduced with 1% hydrogen peroxide in TBS for
20 min. at room temperature (RT) in the dark. The blocking
reagents avidin D and biotin were then added to each slide for
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blocking reagent (Vector Laboratories, Inc., Burlingame, Califor-
nia) for 1 hour at RT. Biotinylated antimouse IgG was pre-labeled
with the anti-pimonidazole antibody for 10 min. and was applied
to slides overnight at 4uC. Liquid DAB (DAKO, Carpinteria,
California) was applied to slides for 5–10 min. to visualize the
reaction. Finally, slides were counterstained with Gill’s Hematox-
ylin (Sigma Chemical Co., St. Louis, MO) for 10 min. and cover-
slipped.
Fluorescent and Confocal Microscopy
Photographs were taken on a Nikon Eclipse 80i with DAPI,
FITC and TRITC filter sets and an Optronics Microfire color
fluorescent camera. Multiple photographs were taken under
different focal planes when necessary and combined using the
Extended Depth of Focus (EDF) function on Nikon NIS Elements
AR 3.0 software. Confocal images were captured on a Zeiss LSM
510 Meta laser scanning confocal microscope and analyzed using
Zeiss LSM image analyzer version 4.0.
Acknowledgments
We acknowledge the staff of the Laboratory Animal Resources at Colorado
State University (CSU) or their animal care. We kindly thank Dr. K.
Andries (Tibotec/Johnson&Johnson, Belgium) for providing TMC207 and
thank the experimental assistance of Lisa Heitmann and Dr. Stefan Ehlers
(Research Center Borstel, Borstel, Germany) for the pimonidazole staining
approach.
Author Contributions
Conceived and designed the experiments: DRH GJR ERD RJB MADG
CCS AJL. Performed the experiments: DRH GJR ERD SCC. Analyzed
the data: DRH GJR RJB MADG AJL. Contributed reagents/materials/
analysis tools: RJB MADG. Wrote the paper: DRH GJR RJB AJL.
References
1. (2003) WHO annual report on global TB control–summary. Wkly Epidemiol
Rec 78: 122–128.
2. (2008) Trends in tuberculosis–United States, 2007. MMWR Morb Mortal Wkly
Rep 57: 281–285.
3. Gomez JE, McKinney JD (2004) M. tuberculosis persistence, latency, and drug
tolerance. Tuberculosis (Edinb) 84: 29–44.
4. Sacchettini JC, Rubin EJ, Freundlich JS (2008) Drugs versus bugs: in pursuit of
the persistent predator Mycobacterium tuberculosis. Nat Rev Microbiol 6:
41–52.
5. Ehlers S (2009) Lazy, dynamic or minimally recrudescent? On the elusive nature
and location of the mycobacterium responsible for latent tuberculosis. Infection
37: 87–95.
6. Flynn JL (2006) Lessons from experimental Mycobacterium tuberculosis
infections. Microbes Infect 8: 1179–1188.
7. Wayne LG, Sramek HA (1994) Metronidazole is bactericidal to dormant cells of
Mycobacterium tuberculosis. Antimicrob Agents Chemother 38: 2054–2058.
8. Hampshire T, Soneji S, Bacon J, James BW, Hinds J, et al. (2004) Stationary
phase gene expression of Mycobacterium tuberculosis following a progressive
nutrient depletion: a model for persistent organisms? Tuberculosis (Edinb) 84:
228–238.
9. Bishai WR (2000) Rekindling old controversy on elusive lair of latent
tuberculosis. Lancet 356: 2113–2114.
10. Parrish NM, Dick JD, Bishai WR (1998) Mechanisms of latency in
Mycobacterium tuberculosis. Trends Microbiol 6: 107–112.
11. Munoz-Elias EJ, Timm J, Botha T, Chan WT, Gomez JE, et al. (2005)
Replication dynamics of Mycobacterium tuberculosis in chronically infected
mice. Infect Immun 73: 546–551.
12. Ryan GJ, Hoff DR, Driver ER, Voskuil MI, Gonzalez-Juarrero M, et al. (2010)
Multiple M. tuberculosis phenotypes in mouse and guinea pig lung tissue
revealed by a dual-staining approach. PLoS ONE [Electronic Resource] 5:
e11108.
13. Canetti G (1955) The Tubercle Bacillus in the Pulmonary Lesion of Man;
Histobacteriology and its bearing on the therapy of pulmonary tuberculosis. New
York: Springer Publishing Company, Inc.
14. Kelly BP, Furney SK, Jessen MT, Orme IM (1996) Low-dose aerosol infection
model for testing drugs for efficacy against Mycobacterium tuberculosis.
Antimicrob Agents Chemother 40: 2809–2812.
15. Lenaerts AJ, Degroote MA, Orme IM (2008) Preclinical testing of new drugs for
tuberculosis: current challenges. Trends Microbiol 16: 48–54.
16. Davies GR, Pym AS, Mitchison DA, Nuermberger EL, Grosset JH (2007)
Evaluation of new antituberculosis drugs in mouse models. Antimicrob Agents
Chemother 51: 403; author reply 403–404.
17. Nuermberger EL (2008) Using animal models to develop new treatments for
tuberculosis. Semin Respir Crit Care Med 29: 542–551.
18. Rhoades ER, Frank AA, Orme IM (1997) Progression of chronic pulmonary
tuberculosis in mice aerogenically infected with virulent Mycobacterium
tuberculosis. Tuber Lung Dis 78: 57–66.
19. Aly S, WagnerK, Keller C, Malm S, Malzan A,et al.(2006) Oxygen status of lung
granulomas in Mycobacterium tuberculosis-infected mice. J Pathol 210: 298–305.
20. Tsai MC, Chakravarty S, Zhu G, Xu J, Tanaka K, et al. (2006) Characterization
of the tuberculous granuloma in murine and human lungs: cellular composition
and relative tissue oxygen tension. Cell Microbiol 8: 218–232.
21. Via LE, Lin PL, Ray SM, Carrillo J, Allen SS, et al. (2008) Tuberculous
granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect
Immun 76: 2333–2340.
22. Turner OC, Basaraba RJ, Orme IM (2003) Immunopathogenesis of pulmonary
granulomas in the guinea pig after infection with Mycobacterium tuberculosis.
Infect Immun 71: 864–871.
23. Lenaerts AJ, Hoff D, Aly S, Ehlers S, Andries K, et al. (2007) Location of
persisting mycobacteria in a Guinea pig model of tuberculosis revealed by
r207910. Antimicrob Agents Chemother 51: 3338–3345.
24. Ordway D, Palanisamy G, Henao-Tamayo M, Smith EE, Shanley C, et al.
(2007) The cellular immune response to Mycobacterium tuberculosis infection in
the guinea pig. J Immunol 179: 2532–2541.
25. Basaraba RJ, Bielefeldt-Ohmann H, Eschelbach EK, Reisenhauer C,
Tolnay AE, et al. (2008) Increased expression of host iron-binding proteins
precedes iron accumulation and calcification of primary lung lesions in
experimental tuberculosis in the guinea pig. Tuberculosis (Edinb) 88: 69–79.
26. Basaraba RJ (2008) Experimental tuberculosis: the role of comparative
pathology in the discovery of improved tuberculosis treatment strategies.
Tuberculosis (Edinb) 88 Suppl 1: S35–47.
27. Lin PL, Rodgers M, Smith L, Bigbee M, Myers A, et al. (2009) Quantitative
comparison of active and latent tuberculosis in the cynomolgus macaque model.
Infection & Immunity 77: 4631–4642.
28. Converse PJ, Dannenberg AM, Jr., Estep JE, Sugisaki K, Abe Y, et al. (1996)
Cavitary tuberculosis produced in rabbits by aerosolized virulent tubercle bacilli.
Infection & Immunity 64: 4776–4787.
29. Al-Moamary MS, Black W, Bessuille E, Elwood RK, Vedal S (1999) The
significance of the persistent presence of acid-fast bacilli in sputum smears in
pulmonary tuberculosis. Chest 116: 726–731.
30. Cegielski JP, Devlin BH, Morris AJ, Kitinya JN, Pulipaka UP, et al. (1997)
Comparison of PCR, culture, and histopathology for diagnosis of tuberculous
pericarditis. J Clin Microbiol 35: 3254–3257.
31. Goel MM, Budhwar P (2007) Immunohistochemical localization of Mycobac-
terium tuberculosis complex antigen with antibody to 38 kDa antigen versus
Ziehl Neelsen staining in tissue granulomas of extrapulmonary tuberculosis.
Indian J Tuberc 54: 24–29.
32. Gutierrez Cancela MM, Garcia Marin JF (1993) Comparison of Ziehl-Neelsen
staining and immunohistochemistry for the detection of Mycobacterium bovis in
bovine and caprine tuberculous lesions. J Comp Pathol 109: 361–370.
33. Kumar N, Tiwari MC, Verma K (1998) AFB staining in cytodiagnosis of
tuberculosis without classical features: a comparison of Ziehl-Neelsen and
fluorescent methods. Cytopathology 9: 208–214.
34. van der Zanden AG, Hoentjen AH, Heilmann FG, Weltevreden EF,
Schouls LM, et al. (1998) Simultaneous detection and strain differentiation of
Mycobacterium tuberculosis complex in paraffin wax embedded tissues and in
stained microscopic preparations. Mol Pathol 51: 209–214.
35. Watrelot-Virieux D, Drevon-Gaillot E, Toussaint Y, Belli P (2006) Comparison
of three diagnostic detection methods for tuberculosis in French cattle. J Vet
Med B Infect Dis Vet Public Health 53: 321–325.
36. Shi L, Jung YJ, Tyagi S, Gennaro ML, North RJ (2003) Expression of Th1-
mediated immunity in mouse lungs induces a Mycobacterium tuberculosis
transcription pattern characteristic of nonreplicating persistence. Proc Natl Acad
Sci U S A 100: 241–246.
37. Somoskovi A, Hotaling JE, Fitzgerald M, O’Donnell D, Parsons LM, et al.
(2001) Lessons from a proficiency testing event for acid-fast microscopy. Chest
120: 250–257.
38. Salfinger M, Pfyffer GE (1994) The new diagnostic mycobacteriology laboratory.
Eur J Clin Microbiol Infect Dis 13: 961–979.
39. Steingart KR, Henry M, Ng V, Hopewell PC, Ramsay A, et al. (2006)
Fluorescence versus conventional sputum smear microscopy for tuberculosis: a
systematic review. Lancet Infect Dis 6: 570–581.
40. Jeyanathan M, Alexander DC, Turenne CY, Girard C, Behr MA (2006)
Evaluation of in situ methods used to detect Mycobacterium avium subsp.
paratuberculosis in samples from patients with Crohn’s disease. J Clin Microbiol
44: 2942–2950.
Visualization of M. tuberculosis in Animal Models
PLoS ONE | www.plosone.org 13 March 2011 | Volume 6 | Issue 3 | e1755041. Yan BS, Pichugin AV, Jobe O, Helming L, Eruslanov EB, et al. (2007)
Progression of pulmonary tuberculosis and efficiency of bacillus Calmette-
Guerin vaccination are genetically controlled via a common sst1-mediated
mechanism of innate immunity. J Immunol 179: 6919–6932.
42. Sissons J, Yan BS, Pichugin AV, Kirby A, Daly MJ, et al. (2009) Multigenic
control of tuberculosis resistance: analysis of a QTL on mouse chromosome 7
and its synergism with sst1. Genes Immun 10: 37–46.
43. Lenaerts AJ, Gruppo V, Brooks JV, Orme IM (2003) Rapid in vivo screening of
experimental drugs for tuberculosis using gamma interferon gene-disrupted
mice. Antimicrob Agents Chemother 47: 783–785.
44. Lenaerts AJ, Gruppo V, Marietta KS, Johnson CM, Driscoll DK, et al. (2005)
Preclinical testing of the nitroimidazopyran PA-824 for activity against
Mycobacterium tuberculosis in a series of in vitro and in vivo models.
Antimicrob Agents Chemother 49: 2294–2301.
45. Hoff DR, Caraway ML, Brooks EJ, Driver ER, Ryan GJ, et al. (2008)
Metronidazole lacks antibacterial activity in guinea pigs infected with
Mycobacterium tuberculosis. Antimicrob Agents Chemother 52: 4137–4140.
46. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, et al. (1993) An
essential role for interferon gamma in resistance to Mycobacterium tuberculosis
infection. J Exp Med 178: 2249.
47. Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, et al. (1993)
Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med
178: 2243–2247.
48. Pearl JE, Saunders B, Ehlers S, Orme IM, Cooper AM (2001) Inflammation and
lymphocyte activation during mycobacterial infection in the interferon-c-
deficient mouse. Cellular Immunology 211: 43–50.
49. Turner OC, Basaraba RJ, Frank AA, Orme IM in Granulomatous Infections and
Inflammation: Cellular and Molecular Mechanisms D. L. Boros, Ed. (ASM Press,
Washington, DC, 2003). pp 65–84.
50. Johnson CM, Pandey R, Sharma S, Khuller GK, Basaraba RJ, et al. (2005) Oral
therapy using nanoparticle encapsulated anti-tuberculosis drugs in guinea pigs
infected with Mycobacterium tuberculosis. Antimicrob Agents Chemother.
51. McMurray DN (2003) Hematogenous reseeding of the lung in low-dose, aerosol-
infected guinea pigs: unique features of the host-pathogen interface in secondary
tubercles. Tuberculosis (Edinb) 83: 131–134.
52. Basaraba RJ, Smith EE, Shanley CA, Orme IM (2006) Pulmonary lymphatics
are primary sites of Mycobacterium tuberculosis infection in guinea pigs infected
by aerosol. Infect Immun 74: 5397–5401.
53. Ordway DJ, Shanley CA, Caraway ML, Orme EA, Bucy DS, et al. (2010)
Evaluation of standard chemotherapy in the guinea pig model of tuberculosis.
Antimicrobial Agents & Chemotherapy 54: 1820–1833.
54. Orme IM (2003) The mouse as a useful model of tuberculosis. Tuberculosis
(Edinb) 83: 112–115.
55. Jayaram R, Shandil RK, Gaonkar S, Kaur P, Suresh BL, et al. (2004) Isoniazid
pharmacokinetics-pharmacodynamics in an aerosol infection model of tubercu-
losis. Antimicrob Agents Chemother 48: 2951–2957.
56. Jayaram R, Gaonkar S, Kaur P, Suresh BL, Mahesh BN, et al. (2003)
Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model
of tuberculosis. Antimicrob Agents Chemother 47: 2118–2124.
57. Nikonenko BV, Sacksteder KA, Hundert S, Einck L, Nacy CA (2008) Preclinical
study of new TB drugs and drug combinations in mouse models. Recent Patents
Anti-Infect Drug Disc 3: 102–116.
58. Arriaga AK, Orozco EH, Aguilar LD, Rook GAW, Pando RH (2002)
Immunological and pathological comparative anaylsis between experimental
latent tuberculous infection and progressive pulmonary tuberculosis. Clin Exp
Immunol 128: 229–237.
59. McMurray DN (2001) Disease model: pulmonary tuberculosis. Trends Mol Med
7: 135–137.
60. Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, et al.
(2000) A small-molecule nitroimidazopyran drug candidate for the treatment of
tuberculosis. Nature 405: 962–966.
61. Ahmad Z, Klinkenberg LG, Pinn ML, Fraig MM, Peloquin CA, et al. (2009)
Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-
resistant, Mycobacterium tuberculosis in the guinea pig. Journal of Infectious
Diseases 200: 1136–1143.
62. Pan H, Yan BS, Rojas M, Shebzukhov YV, Zhou H, et al. (2005) Ipr1 gene
mediates innate immunity to tuberculosis. Nature 434: 767–772.
63. Davis SL, Nuermberger EL, Um PK, Vidal C, Jedynak B, et al. (2009)
Noninvasive pulmonary [18F]-2-fluoro-deoxy-D-glucose positron emission
tomography correlates with bactericidal activity of tuberculosis drug treatment.
Antimicrobial Agents & Chemotherapy 53: 4879–4884.
64. Gil O, Dı ´az I, Vilaplana C, Tapia G, Dı ´az J, et al. (2010) Granuloma
encapsulation is a key factor for containing tuberculosis infection in minipigs.
PLoS ONE 5: e10030.
65. Russell DG, Cardona PJ, Kim MJ, Allain S, Altare F (2009) Foamy
macrophages and the progression of the human tuberculosis granuloma. Nat
Immunol 10: 943–948.
66. Cardona PJ (2007) New insights on the nature of latent tuberculosis infection
and its treatment. Inflamm Allergy Drug Targets 6: 27–39.
67. Peyron P, Vaubourgeix J, Poquet Y, Levillain F, Botanch C, et al. (2008) Foamy
macrophages from tuberculous patients’ granulomas constitute a nutrient-rich
reservoir for M. tuberculosis persistence. PLoS Pathog 4: e1000204.
68. Wayne LG, Hayes LG (1996) An in vitro model for sequential study of shiftdown
of mycobacterium tuberculosis through two stages of nonreplicating persistence.
infect immun 64: 2062–2069.
69. Ly LH, Russell MI, McMurray DN (2008) Cytokine profiles in primary and
secondary pulmonary granulomas of Guinea pigs with tuberculosis. Am J Respir
Cell Mol Biol 38: 455–462.
70. OjhaAea (2008) Growth of Mycobacterium tuberculosis biofilms containing free
mycolic acids and harboring drug tolerant bacteria. Molecular Microbiology;In
Press.
71. Ca ´ceres N, Tapia G, Ojanguren I, Altare F, Gil O, Pinto S, et al. (2009)
Evolution of foamy macrophages in the pulmonary granulomas of experimental
tuberculosis models. Tuberculosis 89: 175–182.
72. Cardona P (2009) A dynamic reinfection hypothesis of latent tuberculosis
infection. Infection 37: 80–86.
73. Smith DW, Balasubramanian V, Wiegeshaus E (1991) A guinea pig model of
experimental airborne tuberculosis for evaluation of the response to chemo-
therapy: the effect on bacilli in the initial phase of treatment. Tubercle 72:
223–231.
74. Hanscheid T, Ribeiro CM, Shapiro HM, Perlmutter NG (2007) Fluorescence
microscopy for tuberculosis diagnosis. Lancet Infect Dis 7: 236–237.
75. Kojima K, Niri M, Setoguchi K, Tsuda I, Tatsumi N (1989) An automated
optoelectronic reticulocyte counter. Am J Clin Pathol 92: 57–61.
76. Oster G (1951) [Fluorescence of auramine O in the presence of nucleic acid.].
C R Hebd Seances Acad Sci 232: 1708–1710.
77. Seiler P, Ulrichs T, Bandermann S, Pradl L, Jorg S, et al. (2003) Cell-wall
alterations as an attribute of Mycobacterium tuberculosis in latent infection.
J Infect Dis 188: 1326–1331.
78. Ulrichs T, Lefmann M, Reich M, Morawietz L, Roth A, et al. (2005) Modified
immunohistological staining allows detection of Ziehl-Neelsen-negative Myco-
bacterium tuberculosis organisms and their precise localization in human tissue.
J Pathol 205: 633–640.
79. Ulrichs T, Kaufmann SH (2006) New insights into the function of granulomas in
human tuberculosis. J Pathol 208: 261–269.
80. Rosenthal IM, Williams K, Tyagi S, Vernon AA, Peloquin CA, et al. (2005)
Weekly Moxifloxacin and Rifapentine is More Active than the Denver Regimen
in Murine Tuberculosis. Am J Respir Crit Care Med.
81. Nuermberger EL, Yoshimatsu T, Tyagi S, O’Brien RJ, Vernon AN, et al. (2004)
Moxifloxacin-containing regimen greatly reduces time to culture conversion in
murine tuberculosis. Am J Respir Crit Care Med 169: 421–426.
82. Gill WP, Harik NS, Whiddon MR, Liao RP, Mittler JE, et al. (2009) A
replication clock for Mycobacterium tuberculosis. Nat Med 15: 211–214.
83. Eum SY, Kong JH, Hong MS, Lee YJ, Kim JH, et al. (2009) Neutrophils are the
predominant infected phagocytic cells in the airways of patients with active
pulmonary tuberculosis. Chest 137: 122–128.
84. Brandt L, Skeiky YA, Alderson MR, Lobet Y, Dalemans W, et al. (2004) The
protective effect of the Mycobacterium bovis BCG vaccine is increased by
coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion
polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect Immun 72:
6622–6632.
85. Brooks JV, Orme IM (1998) Evaluation of once-weekly therapy for tuberculosis
using isoniazid plus rifamycins in the mouse aerosol infection model. Antimicrob
Agents Chemother 42: 3047–3048.
86. Kraft SL, Dailey D, Kovach M, Stasiak KL, Bennett J, et al. (2004) Magnetic
resonance imaging of pulmonary lesions in guinea pigs infected with
Mycobacterium tuberculosis. Infect Immun 72: 5963–5971.
Visualization of M. tuberculosis in Animal Models
PLoS ONE | www.plosone.org 14 March 2011 | Volume 6 | Issue 3 | e17550